CORONA Remedies profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026
Returns
24.8%24.8%
15.4%15.4%
30.3%30.3%
23.1%22.2%
Margins
21.4%20.9%
18.2%18.2%
17.4%17.1%
13.3%13.2%
13.3%13.2%
3.9%3.9%
Additional
23.6%23.0%
24.8%24.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,217.40

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity24.7924.79
Return on Assets15.3615.36
Return on Capital Employed30.2830.28
Return on Invested Capital22.1623.09
Margins
EBITDA Margin20.9121.44
Operating Margin18.2118.21
Pretax Margin17.1317.38
Net Income Margin13.1913.28
Net Income to Common Margin13.1913.28
FCF Margin3.943.94
Additional
Effective Tax Rate23.0023.64
Sustainable Growth Rate24.7924.79
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.